Cilostazol in Acute Ischemic Stroke Trial

Cilostazol in Acute Ischemic Stroke Trial - Cilostazol in Acute Ischemic Stroke Trial (CAIST-J)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000673

Enrollment

350

Registered

2008-12-31

Start date

2006-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke

Interventions

Patients will be randomly selected to receive cilostazol. Patients will also be randomly selected to receive treatment with conventional therapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Admission within 72 hours after the onset of ischemic stroke 2. NIHSS score 14>=

Exclusion criteria

Exclusion criteria: 1.cardiogenic embolism 2.previous ischemic stroke episode within 6 months 3.hemorrhagic stroke 4.consciousness disturbance 5.prestroke modified Rankin Scale 2<= 6.malignancy 7.pregnancy 8.allergic to cilostazol

Design outcomes

Primary

Measure	Time frame
modified Rankin scale 0-2 at 3 month	—

Secondary

Measure	Time frame
Recurrence of stroke, NIHSS, JSS, Barthel Indes, modified Rankin Scale, Zung, MMSE, Neurological deterioration, Pneumonia	—

Countries

Japan

Contacts

Public ContactHaruhiko Hoshino

Keio University School of Medicine Department of Neurology

hhoshino-keio@umin.ac.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026